Business Context and Reporting Period
This Form 8-K is filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on May 9, 2022. The report addresses two critical corporate events: a deficiency notice from Nasdaq regarding the company's stock bid price and a determination to restate financial statements due to revenue recognition errors.
Key Financial Metrics and Status
- Stock Price Status: The closing bid price for common stock was below the $1.00 per share minimum requirement for 30 consecutive business days prior to May 9, 2022.
- Financial Restatement Impact: The company estimates a cumulative misstatement of deferred revenue and accumulated deficit of less than $10 million as of December 31, 2021.
- Cash Flow and Expenses: The company expects the restatement to have no effect on previously reported operating expenses, cash flows, or cash and short-term investments.
- Debt and Liquidity: The filing text does not provide specific values for debt or liquidity positions.
Material Changes and Events
Nasdaq Delisting Notice (Item 3.01)
MEI Pharma received a deficiency letter from Nasdaq for failing to meet the $1.00 minimum bid price requirement. The company has an initial 180-day compliance period ending November 7, 2022, to regain compliance. Failure to comply may lead to delisting, though an additional 180-day period may be available if the company meets other listing standards and effects a reverse stock split.
Financial Restatement (Item 4.02)
The Audit Committee concluded that financial statements from June 30, 2020, through December 31, 2021, contain material errors regarding revenue recognition under the cost-to-cost method for the agreement with Kyowa Kirin Co., Ltd. (KKC). Consequently:
- Previously issued 10-K and 10-Q reports for these periods should no longer be relied upon.
- The company will file amendments to restate these periods.
- Revenue was overstated in some quarters and understated in others.
Outlook, Risks, and Management Commentary
- Internal Controls: Management expects to report at least one material weakness in internal control over financial reporting following the analysis of the restatement causes.
- Compliance Strategy: The company intends to monitor its stock price and may consider a reverse stock split to regain Nasdaq compliance.
- Reporting Delays: The company expects to file an extension (Form 12b-25) for its Quarterly Report for the period ended March 31, 2022.
- Risks: There is no assurance the company will regain compliance with Nasdaq listing requirements or that the quantification of financial errors will not result in further material adjustments.
Investor Verification Checklist
- Verify the exact quantification of the revenue restatement once the amended 10-K and 10-Q filings are released.
- Monitor the company's stock price to determine if it meets the $1.00 threshold for 10 consecutive days before the November 7, 2022, deadline.
- Review the upcoming disclosure regarding the specific material weaknesses in internal controls.
- Confirm the filing status of the extension for the Q1 2022 quarterly report.